Medical School or Training
University of Michigan Medical School, 1988
Children's Hospital of Boston, Pediatrics, MA, 1991
Children's Hospital of Boston, Endocrinology, MA, 1994
American Diabetes Association
Pediatric Endocrine Society (formerly Lawson Wilkins Pediatric Endocrine Society)
Type 1 diabetes in children and the use of technology to improve diabetes care and control; artificial pancreas; novel approaches to general pediatric endocrine problems.
Mike Wood, MD, joined the Pediatric Endocrinology Division at C.S. Mott Children's Hospital in 2013. He attended the University of Michigan for both undergraduate studies and medical school. After completing medical school, Dr. Wood served his internship and pediatric residency, as well as a pediatric endocrinology fellowship, at Harvard’s Boston Children’s Hospital from 1988–1994. From 1994 until 2013, Dr. Wood was the Division Chief of Pediatric Endocrinology at the Helen DeVos Children’s Hospital in Grand Rapids, Michigan. He retains a role there as Staff Pediatrician-Associate Status, as well as at Sparrow Hospital in Lansing, Michigan, where he is a Staff Pediatrician-Active Status.
Dr. Wood's main clinical research focus is type 1 diabetes in children. He is particularly interested in the use of technology to improve diabetes care and control, with an eventual goal of participation in the first national studies of the artificial pancreas in children. To this end, he has been either the principal investigator or co-investigator on national clinical trials since 2006.
In addition, Dr. Wood has participated in two investigator-initiated studies within the Pediatric Endocrinology Division. Dr. Wood and his colleagues have collated their data on our well-controlled insulin pump patients in an effort to demonstrate a predictive model for insulin dosing based on age. They have also recently completed a prospective phase 4 crossover study comparing insulin glulisine to insulin aspart on postprandial glucose levels in prepubertal children.
Other research performed by Dr. Wood includes post-marketing surveillance studies for growth hormone and IGF-1; retrospective reviews of early and late radioactive iodine uptake in children with Graves’ disease; describing a cohort of hypocalcemic infants with seizures due to maternal Vitamin D deficiency; and reviewing low dose vs. high dose Cosyntropin dosing in children undergoing assessment of the hypothalamic-pituitary-adrenal axis.